Request Demo
Last update 08 May 2025
IFNGR x IL-6R x IL-10R x IL-1β x CCL2
Last update 08 May 2025
Related
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
NCT03860532
Phase I Randomized,Double-Blind,Placebo-controlled Trial in Healthy Male Voluteers To Examine the Safety,Tolerability,and Pharmacokinetics of HMPL-011 After A Single Dose.
ACTRN12610000287033
A phase I randomized, double-blind, placebo-controlled study inhealthy male volunteers to examine the safety, tolerability, and pharmacokinetics of HMPL-011 after multiple dosing for 14days.
ACTRN12609000891224
Phase 1 Randomized, Double-Blind, Placebo-Controlled Trial in Healthy Male Volunteers To Examine The Safety, Tolerability, And Pharmacokinetics Of HMPL-011 After A Single Dose
100 Clinical Results associated with IFNGR x IL-6R x IL-10R x IL-1β x CCL2
Login to view more data
100 Translational Medicine associated with IFNGR x IL-6R x IL-10R x IL-1β x CCL2
Login to view more data
Login to view more data
Analysis
Perform a panoramic analysis of this field.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free